WHAT IS CLAIMED IS:

1. A compound of the formula I:



I

wherein:

R^1 is selected from:

hydrogen,

$-C_{0-6}alkyl-Y-(C_{1-6}alkyl)-$, and

$-(C_{0-6}alkyl)-Y-(C_{0-6}alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl)$,

where Y is selected from:

a single bond, -O-, -S-, -SO-, $-SO_2-$, and $-NR^{10}-$,

and where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) $-O-C_{1-3}alkyl$, and

(d) trifluoromethyl,

(e) $C_{1-3}alkyl$,

(f) $-O-C_{1-3}alkyl$,

(g) $-CO_2R^9$, wherein R^9 is independently selected from: hydrogen, C_{1-6} alkyl, C_{5-6} cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, $C_{1-3}alkyl$, $C_{1-3}alkoxy$ and trifluoromethyl,

(h) -CN,

(i) heterocycle,

(j) $-NR^9R^{10}$,

(k) $-NR^9COR^{10}$,

(l) $-NR^9SO_2R^{10}$, and

(m) $-CONR^9R^{10}$;

R^2 is selected from:

$(C_{0-6}alkyl)$-phenyl and $(C_{0-6}alkyl)$-heterocycle,

where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,
(b) hydroxy,
(c) $-O-C_{1-3}alkyl$,
(d) trifluoromethyl, and
(e) $-C_{1-3}alkyl$,

and where the phenyl and the heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) $C_{1-6}alkyl$,
(f) $C_{3-7}cycloalkyl$,
(g) $-O-C_{1-6}alkyl$,
(h) $-O-C_{3-7}cycloalkyl$,
(i) $-SCF_3$,
(j) $-S-C_{1-6}alkyl$,
(k) $-SO_2-C_{1-6}alkyl$,
(l) phenyl,
(m) heterocycle,
(n) $-CO_2R^9$,
(o) -CN,
(p) $-NR^9R^{10}$,
(q) $-NR^9-SO_2-R^{10}$,
(r) $-SO_2-NR^9R^{10}$, and
(s) $-CONR^9R^{10}$;

R^3 is selected from:

(C_{0-6}alkyl)-heterocycle,

where the alkyl is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl, and
(d) trifluoromethyl,

and where the heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$;

R^4 is selected from:

(a) hydrogen,
(b) hydroxy,
(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-hydroxy,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -$CONR^9R^{10}$, and
(h) -CN;

R^5 and R^6 are independently selected from:

(a) hydrogen,
(b) hydroxy,
(c) C_{1-6}alkyl,
(d) C_{1-6}alkyl-hydroxy,

(e) -O-C_{1-3}alkyl,

(f) oxo, and

(g) halo;

R^{10} is independently selected from:
hydrogen, C_{1-6} alkyl, benzyl, phenyl, and C_{1-6} alkyl-C_{3-6} cycloalkyl,
which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C_{1-3}alkyl, C_{1-3}alkoxy and
trifluoromethyl;

n is an integer which is 0 or 1;

and pharmaceutically acceptable salts thereof and individual diastereomers thereof.

2. The compound of Claim 1 wherein R^1 is selected from:
-C_{1-6}alkyl, -C_{0-6}alkyl-O-C_{1-6}alkyl-, -C_{0-6}alkyl-S-C_{1-6}alkyl-, and
-(C_{0-6}alkyl)-(C_{3-7}cycloalkyl)-(C_{0-6}alkyl),
where the alkyl and the cycloalkyl are unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:

(a) halo,

(b) hydroxy,

(c) -O-C_{1-3}alkyl,

(d) trifluoromethyl,

(f) C_{1-3}alkyl,

(g) -O-C_{1-3}alkyl,

(h) -CO_2R^9, wherein R^9 is independently selected from: hydrogen, C_{1-6} alkyl, C_{5-6} cycloalkyl, benzyl or phenyl, which is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from: halo, C_{1-3}alkyl, C_{1-3}alkoxy and trifluoromethyl,

(i) -CN,

(j) -NR^9R^{10}, and

(k) -$CONR^9R^{10}$.

3. The compound of Claim 1 wherein R^1 is selected from:

(1) -C1-6alkyl, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from:
  (a) halo,
  (b) hydroxy,
  (c) -O-C1-3alkyl, and
  (d) trifluoromethyl,
(2) -C0-6alkyl-O-C1-6alkyl-, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from:
  (a) halo, and
  (b) trifluoromethyl,
(3) -C0-6alkyl-S-C1-6alkyl-, which is unsubstituted or substituted with 1-6 substituents where the substituents are independently selected from:
  (a) halo, and
  (b) trifluoromethyl,
(4) -(C3-5cycloalkyl)-(C0-6alkyl), which is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
  (a) halo,
  (b) hydroxy,
  (c) -O-C1-3alkyl, and
  (d) trifluoromethyl.

4. The compound of Claim 1 wherein R^1 is selected from:
(1) -CH3,
(2) -CH2CH3,
(3) -CH(CH3)2,
(4) -CH2CH2CH3,
(5) -CH2CH(CH3)2,
(6) -cyclopropyl,
(7) -cyclobutyl,
(8) -cyclopentyl,
(9) -CH2-cyclopropyl,
(10) -CH2-cyclobutyl,
(11) -CH2-cyclopentyl,
(12) -CH2OH,

(13) -C(CH3)2(OH),
(14) -C(CH2OH)(CH3)2,
(15) -(OH)cyclobutyl,
(16) -(OH)cyclopentyl,
(17) -C(CH3)2(NHCOCH3),
(18) -C(CO2H)(CH3)2,
(19) -O-CH3,
(20) -O-cyclopentyl,
(21) -O-CH(CH3)2,
(22) -S-CH3,
(23) -S-CF3,
(24) -SO2-CH3,
(25) -S-CH(CH3)2,
(26) -SO2-CH(CH3)2, and
(27) -NH-SO2-CH3.

5. The compound of Claim 1 wherein R^2 is selected from:
-(C0-4alkyl)-phenyl and -(C0-4alkyl)-heterocycle,
where heterocycle is selected from:
furanyl, imidazolyl, oxadiazolyl, oxazolyl, pyrazolyl, pyrazinyl, pyridyl, pyridazinyl, pyrimidyl, pyrrolyl, thiadiazolyl, thiazolyl, thienyl, and triazolyl, and N-oxides thereof,
where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C1-3alkyl, and
(d) trifluoromethyl,
and where the phenyl or heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,

(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) -CO_2R^9,
(h) -S-C_{1-3}alkyl,
(i) -SO_2-C_{1-3}alkyl,
(j) -SCF_3,
(k) -CO_2R^9,
(l) -NR^9R^{10},
(m) -NR^9-SO_2-R^{10},
(n) -SO_2-NR^9R^{10}, and
(o) -$CONR^9R^{10}$.

6. The compound of Claim 1 wherein R^2 is selected from:
-(C_{0-4}alkyl)-phenyl and -(C_{0-4}alkyl)-heterocycle,
where heterocycle is selected from: pyridyl, pyridazinyl, and N-oxides thereof,
where the alkyl is unsubstituted or substituted with 1-7 substituents where the substituents are independently selected from:
(a) halo,
(b) hydroxy,
(c) -O-C_{1-3}alkyl, and
(d) trifluoromethyl,
and where the phenyl or heterocycle is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:
(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) C_{1-3}alkyl,
(f) -O-C_{1-3}alkyl,
(g) -CO_2-C_{1-3}alkyl,
(h) -CO_2H,
(i) -S-C_{1-3}alkyl,
(j) -SO_2-C_{1-3}alkyl,
(k) -SCF_3,

(l) $-NH_2$,
(m) $-NH-SO_2-C_{1-3}alkyl$, and
(n) $-SO_2-NH_2$.

7. The compound of Claim 1 wherein R^2 is selected from:
$-CH_2$-phenyl and $-CH_2$-heterocycle,
where heterocycle is selected from: pyridyl, pyridazinyl, and N-oxides thereof,
and where the phenyl or heterocycle is unsubstituted or substituted with 1-3 substituents
where the substituents are independently selected from:

(a) halo,
(b) trifluoromethyl,
(c) trifluoromethoxy,
(d) hydroxy,
(e) $C_{1-3}alkyl$,
(f) $-O-C_{1-3}alkyl$,
(g) $-CO_2-C_{1-3}alkyl$,
(h) $-CO_2H$,
(i) $-S-C_{1-3}alkyl$,
(j) $-SO_2-C_{1-3}alkyl$,
(k) $-SCF_3$,
(l) $-NH_2$,
(m) $-NH-SO_2-C_{1-3}alkyl$, and
(n) $-SO_2-NH_2$.

8. The compound of Claim 1 wherein R^2 is selected from:

(1) $-CH_2$-(phenyl),
(2) $-CH_2$-(4-bromophenyl),
(3) $-CH_2$-(3-chlorophenyl),
(4) $-CH_2$-(3,5-difluorophenyl),
(5) $-CH_2$-((2-trifluoromethyl)phenyl),
(6) $-CH_2$-((3-trifluoromethyl)phenyl),
(7) $-CH_2$-((4-trifluoromethyl)phenyl),
(8) $-CH_2$-((3-trifluoromethoxy)phenyl),
(9) $-CH_2$-((3-trifluoromethylthio)phenyl),

(10) -CH_2-((3-trifluoromethoxy-5-thiomethyl)phenyl),
(11) -CH_2-((3-trifluoromethoxy-5-methoxy)phenyl),
(12) -CH_2-((3-trifluoromethoxy-5-methanesulfonyl)phenyl),
(13) -CH_2-((3-trifluoromethoxy-5-amino)phenyl),
(14) -CH_2-((3-trifluoromethoxy-5-aminomethanesulfonyl)phenyl),
(15) -CH_2-((3-trifluoromethoxy-5-sulfonylamino)phenyl),
(16) -CH_2-((3,5-bis-trifluoromethyl)phenyl),
(17) -CH_2-((3-fluoro-5-trifluoromethyl)phenyl),
(18) -$CH(CH_3)$-((3,5-bis-trifluoromethyl)phenyl),
(19) -$C(CH_3)2$-((3,5-bis-trifluoromethyl)phenyl),
(20) -CH_2-(4-(2-trifluoromethyl)pyridyl),
(21) -CH_2-(5-(3-trifluoromethyl)pyridyl),
(22) -CH_2-(5-(3-trifluoromethyl)pyridazinyl),
(23) -CH_2-(4-(2-trifluoromethyl)pyridyl-N-oxide), and
(24) -CH_2-(5-(3-trifluoromethyl)pyridyl-N-oxide).

9. The compound of Claim 1 wherein R^3 is heterocycle,
where the heterocycle is selected from: imidazole, pyrimidyl, triazole or tetrazole, and
where the heterocycle is unsubstituted or substituted with 1-5 substituents where the substituents are independently selected from:
(a) halo,
(b) trifluoromethyl,
(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl,
(f) -CO_2R^9,
(g) -CN,
(h) -NR^9R^{10}, and
(i) -$CONR^9R^{10}$.

10. The compound of Claim 1 wherein R^3 is heterocycle,
where the heterocycle is unsubstituted or substituted with 1-3 substituents where the substituents are independently selected from:
(a) halo,

(c) hydroxy,
(d) C_{1-3}alkyl,
(e) -O-C_{1-3}alkyl, and
(f) -CO_2R^9.

11. The compound of Claim 1 wherein R^3 is selected from: imidazole, pyrimidyl, triazole or tetrazole.

12. The compound of Claim 1 wherein R^3 is selected from:



13. The compound of Claim 1 wherein R^4 is selected from:
(a) hydrogen,
(b) hydroxy,
(c) -CO_2H,
(d) -CO_2C_{1-6}alkyl,
(e) -CN.

14. The compound of Claim 1 wherein R^4 is hydrogen.

15. The compound of Claim 1 wherein R^5 and R^6 are independently selected from:

(a) hydrogen,
(b) hydroxy,
(c) $-CH_3$,
(d) $-O-CH_3$, and
(e) oxo.

16. The compound of Claim 1 wherein R^5 is independently selected from:

(a) hydrogen,
(b) $-CH_3$, and
(c) $-O-CH_3$.

17. A compound which is selected from the group consisting of the title compounds of the Examples, and pharmaceutically acceptable salts and individual diastereomers thereof.

18. A pharmaceutical composition which comprises an inert carrier and a compound of Claim 1.

19. A method for modulation of chemokine receptor activity in a mammal in need thereof which comprises the administration of an effective amount of the compound of Claim 1.

20. A method for treating, ameliorating or controlling an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.

21. A method for reducing the risk of an inflammatory or immunoregulatory disorder or disease which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.

22. A method for treating, ameliorating or controlling rheumatoid arthritis which comprises administering to a patient in need thereof an effective amount of the compound of Claim 1.